2025 Q4 -tulosraportti
55 päivää sitten
‧46 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 6 517 | - | - | ||
| 4 060 | - | - | ||
| 7 266 | - | - | ||
| 1 235 | - | - | ||
| 7 939 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 989 398 | 2 989 398 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 989 398 | 2 989 398 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 13.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 19.2. | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 päivä sittenAI answer to the question of whether there is a risk of bankruptcy Yes — there is a real risk that Oncopeptides AB will have to raise additional capital or, in an extreme case, be forced to cease operations if revenues do not continue to grow and the company cannot finance its operations in a long-term sustainable way. This is evident both from the company's own reports and the financing that has actually occurred after the latest annual report (2024). 📌 Capital injection after the latest annual report • In late summer 2025, the company carried out a rights issue that provided approximately 150 million SEK before transaction costs, which was fully subscribed and gave the company a significant injection of liquid funds to finance continued commercialization of Pepaxti and development of pipeline projects. • In early 2026, the board decided on a further rights issue of approximately 200 million SEK, also with the aim of strengthening the company's financial position, supporting continued commercialization and financing of clinical development projects such as planned studies for new indications. ⚠️ Decreased confidence in the latest issue. • Research company Oncopeptides' rights issue was subscribed to approximately 62 percent with and without subscription rights. Against this background, approximately 33 percent of the issue will be allocated to guarantors, which means that the company will receive approximately 190 million SEK before issue costs, according to a press release. • Oncopeptides AB has received a flagging notification from HealthCap VI, L.P. regarding a change in its shareholding. The notification, triggered by a corporate event, indicates that HealthCap VI, L.P.'s holding has fallen below the 5%-ownership threshold. The reported date for the transaction is 2026-03-27. These capital raisings show that the company has been able to attract new capital from the market, which reduces the risk of short-term bankruptcy compared to if the cash position had remained unchanged. At the same time, issues mean dilution for shareholders, and the need for more capital in the future may still arise if revenues do not develop quickly enough. ⸻ 📉 Risks in operations 1) Going concern risk according to the annual report In the latest annual report (2024), the company states that there is significant uncertainty regarding the ability to continue operations without additional financing unless sales continue to develop positively. 2) Costs vs revenues The company is still loss-making, and even if revenues from Pepaxti increase from previous levels, they are still far below the cost base. If revenues grow slower than costs, there is a risk of continued financing needs. There is no guarantee that such transactions can always be carried out on favorable terms or to a sufficient extent. ⸻ 💡 Possible scenarios going forward ✔️ Positive: If revenues continue to increase and reach a positive cash flow in 2027, the company can become self-financing and reduce the need for future issues. ⚠️ Financing needs: If growth is weaker than expected or if costs increase, the company may need more issues or other forms of external financing — which means dilution for shareholders and risks for share price development. ❌ Extreme scenario: In a worst-case scenario where revenues would fall sharply and new financing solutions are not possible on reasonable terms, there is a theoretical risk that the company will be forced to cease operations or undergo reconstruction. ⸻ Summary: Yes — there may be a risk of bankruptcy in an extreme case if revenues do not increase while costs are high and financing opportunities are absent. However, the company has actively injected capital through several issues during 2025 and 2026, which improves the cash position and provides time for sales development. Continued revenue growth is, however, crucial to avoid further issues and reduce the going concern risk. Text written by AI.
·1 päivä sittenWhat do you good people think about the stock?
·10 t sittenTremendous selling pressure here now. It seems that the small uptick managed to shake out more who wanted to get rid of shares!·9 t sittenI'm not thinking about the outcome, but about the quantity of shares that are desired to be sold at this level.
·2 päivää sittenNew important data presented "Proof of concept" https://www.nordnet.se/marknaden/nyheter/1272ccec-07a1-4689-b835-0dd5e93c9bfa
·2 päivää sittenFurthermore, the doctors' strike is scheduled… The Doctors' Association CESM has called for a "rolling" indefinite strike, which means that work will be laid down for a specific week each month: March: 16-20 March April: 27 April – 30 April May: 18 May – 22 May June: 15 June – 19 June July: 13 July – 17 July September: 14 September – 18 September October: 19 October – 23 October November: 16 November – 20 November December: 14 December – 18 December
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
55 päivää sitten
‧46 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenAI answer to the question of whether there is a risk of bankruptcy Yes — there is a real risk that Oncopeptides AB will have to raise additional capital or, in an extreme case, be forced to cease operations if revenues do not continue to grow and the company cannot finance its operations in a long-term sustainable way. This is evident both from the company's own reports and the financing that has actually occurred after the latest annual report (2024). 📌 Capital injection after the latest annual report • In late summer 2025, the company carried out a rights issue that provided approximately 150 million SEK before transaction costs, which was fully subscribed and gave the company a significant injection of liquid funds to finance continued commercialization of Pepaxti and development of pipeline projects. • In early 2026, the board decided on a further rights issue of approximately 200 million SEK, also with the aim of strengthening the company's financial position, supporting continued commercialization and financing of clinical development projects such as planned studies for new indications. ⚠️ Decreased confidence in the latest issue. • Research company Oncopeptides' rights issue was subscribed to approximately 62 percent with and without subscription rights. Against this background, approximately 33 percent of the issue will be allocated to guarantors, which means that the company will receive approximately 190 million SEK before issue costs, according to a press release. • Oncopeptides AB has received a flagging notification from HealthCap VI, L.P. regarding a change in its shareholding. The notification, triggered by a corporate event, indicates that HealthCap VI, L.P.'s holding has fallen below the 5%-ownership threshold. The reported date for the transaction is 2026-03-27. These capital raisings show that the company has been able to attract new capital from the market, which reduces the risk of short-term bankruptcy compared to if the cash position had remained unchanged. At the same time, issues mean dilution for shareholders, and the need for more capital in the future may still arise if revenues do not develop quickly enough. ⸻ 📉 Risks in operations 1) Going concern risk according to the annual report In the latest annual report (2024), the company states that there is significant uncertainty regarding the ability to continue operations without additional financing unless sales continue to develop positively. 2) Costs vs revenues The company is still loss-making, and even if revenues from Pepaxti increase from previous levels, they are still far below the cost base. If revenues grow slower than costs, there is a risk of continued financing needs. There is no guarantee that such transactions can always be carried out on favorable terms or to a sufficient extent. ⸻ 💡 Possible scenarios going forward ✔️ Positive: If revenues continue to increase and reach a positive cash flow in 2027, the company can become self-financing and reduce the need for future issues. ⚠️ Financing needs: If growth is weaker than expected or if costs increase, the company may need more issues or other forms of external financing — which means dilution for shareholders and risks for share price development. ❌ Extreme scenario: In a worst-case scenario where revenues would fall sharply and new financing solutions are not possible on reasonable terms, there is a theoretical risk that the company will be forced to cease operations or undergo reconstruction. ⸻ Summary: Yes — there may be a risk of bankruptcy in an extreme case if revenues do not increase while costs are high and financing opportunities are absent. However, the company has actively injected capital through several issues during 2025 and 2026, which improves the cash position and provides time for sales development. Continued revenue growth is, however, crucial to avoid further issues and reduce the going concern risk. Text written by AI.
- ·1 päivä sittenWhat do you good people think about the stock?·10 t sittenTremendous selling pressure here now. It seems that the small uptick managed to shake out more who wanted to get rid of shares!·9 t sittenI'm not thinking about the outcome, but about the quantity of shares that are desired to be sold at this level.
- ·2 päivää sittenNew important data presented "Proof of concept" https://www.nordnet.se/marknaden/nyheter/1272ccec-07a1-4689-b835-0dd5e93c9bfa
- ·2 päivää sittenFurthermore, the doctors' strike is scheduled… The Doctors' Association CESM has called for a "rolling" indefinite strike, which means that work will be laid down for a specific week each month: March: 16-20 March April: 27 April – 30 April May: 18 May – 22 May June: 15 June – 19 June July: 13 July – 17 July September: 14 September – 18 September October: 19 October – 23 October November: 16 November – 20 November December: 14 December – 18 December
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 6 517 | - | - | ||
| 4 060 | - | - | ||
| 7 266 | - | - | ||
| 1 235 | - | - | ||
| 7 939 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 989 398 | 2 989 398 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 989 398 | 2 989 398 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 13.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 19.2. | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
2025 Q4 -tulosraportti
55 päivää sitten
‧46 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 13.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 19.2. | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenAI answer to the question of whether there is a risk of bankruptcy Yes — there is a real risk that Oncopeptides AB will have to raise additional capital or, in an extreme case, be forced to cease operations if revenues do not continue to grow and the company cannot finance its operations in a long-term sustainable way. This is evident both from the company's own reports and the financing that has actually occurred after the latest annual report (2024). 📌 Capital injection after the latest annual report • In late summer 2025, the company carried out a rights issue that provided approximately 150 million SEK before transaction costs, which was fully subscribed and gave the company a significant injection of liquid funds to finance continued commercialization of Pepaxti and development of pipeline projects. • In early 2026, the board decided on a further rights issue of approximately 200 million SEK, also with the aim of strengthening the company's financial position, supporting continued commercialization and financing of clinical development projects such as planned studies for new indications. ⚠️ Decreased confidence in the latest issue. • Research company Oncopeptides' rights issue was subscribed to approximately 62 percent with and without subscription rights. Against this background, approximately 33 percent of the issue will be allocated to guarantors, which means that the company will receive approximately 190 million SEK before issue costs, according to a press release. • Oncopeptides AB has received a flagging notification from HealthCap VI, L.P. regarding a change in its shareholding. The notification, triggered by a corporate event, indicates that HealthCap VI, L.P.'s holding has fallen below the 5%-ownership threshold. The reported date for the transaction is 2026-03-27. These capital raisings show that the company has been able to attract new capital from the market, which reduces the risk of short-term bankruptcy compared to if the cash position had remained unchanged. At the same time, issues mean dilution for shareholders, and the need for more capital in the future may still arise if revenues do not develop quickly enough. ⸻ 📉 Risks in operations 1) Going concern risk according to the annual report In the latest annual report (2024), the company states that there is significant uncertainty regarding the ability to continue operations without additional financing unless sales continue to develop positively. 2) Costs vs revenues The company is still loss-making, and even if revenues from Pepaxti increase from previous levels, they are still far below the cost base. If revenues grow slower than costs, there is a risk of continued financing needs. There is no guarantee that such transactions can always be carried out on favorable terms or to a sufficient extent. ⸻ 💡 Possible scenarios going forward ✔️ Positive: If revenues continue to increase and reach a positive cash flow in 2027, the company can become self-financing and reduce the need for future issues. ⚠️ Financing needs: If growth is weaker than expected or if costs increase, the company may need more issues or other forms of external financing — which means dilution for shareholders and risks for share price development. ❌ Extreme scenario: In a worst-case scenario where revenues would fall sharply and new financing solutions are not possible on reasonable terms, there is a theoretical risk that the company will be forced to cease operations or undergo reconstruction. ⸻ Summary: Yes — there may be a risk of bankruptcy in an extreme case if revenues do not increase while costs are high and financing opportunities are absent. However, the company has actively injected capital through several issues during 2025 and 2026, which improves the cash position and provides time for sales development. Continued revenue growth is, however, crucial to avoid further issues and reduce the going concern risk. Text written by AI.
- ·1 päivä sittenWhat do you good people think about the stock?·10 t sittenTremendous selling pressure here now. It seems that the small uptick managed to shake out more who wanted to get rid of shares!·9 t sittenI'm not thinking about the outcome, but about the quantity of shares that are desired to be sold at this level.
- ·2 päivää sittenNew important data presented "Proof of concept" https://www.nordnet.se/marknaden/nyheter/1272ccec-07a1-4689-b835-0dd5e93c9bfa
- ·2 päivää sittenFurthermore, the doctors' strike is scheduled… The Doctors' Association CESM has called for a "rolling" indefinite strike, which means that work will be laid down for a specific week each month: March: 16-20 March April: 27 April – 30 April May: 18 May – 22 May June: 15 June – 19 June July: 13 July – 17 July September: 14 September – 18 September October: 19 October – 23 October November: 16 November – 20 November December: 14 December – 18 December
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 6 517 | - | - | ||
| 4 060 | - | - | ||
| 7 266 | - | - | ||
| 1 235 | - | - | ||
| 7 939 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 989 398 | 2 989 398 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 2 989 398 | 2 989 398 | 0 | 0 |